CSIR in the news..

An aggregation of news on the web about CSIR and its laboratories

US firm to market molecules developed by IMTECH

27 November 2010

CHANDIGARH: Nostrum Pharmaceuticals, the US, has obtained the worldwide licence to develop and commercialise the third and fourth generation thrombolytic molecules developed by city-based Institute of Microbial Technology (IMTECH).

The technology has been transferred by IMTECH as part of a 150-million US dollars deal in milestone payments and royalties.

The agreement was signed in New Delhi in the presence of Union Minister of Science and Technology Kapil Sibal and Prof Samir K Brahmachari, Director General, Council for Scientific and Industrial Research.

In the recent past, IMTECH has developed safe, low-cost clot busters that have received a good response from the medical fraternity. These were developed after a long research by IMTECH director Dr Girish Sahni and his team. Dr Sahni said the fourth generation clot-busters also prevent re-occlusion.

Source: http://www.indianexpress.com/news/us-firm-to-market-molecules-developed-by-imtech/716890/

Advertisements

Written by csirindia

November 27, 2010 at 10:05 am

Posted in IMTECH

%d bloggers like this: